BioLineRx (NASDAQ:BLRX) vs. CytoDyn (OTCMKTS:CYDY) Financial Contrast

BioLineRx (NASDAQ:BLRX) and CytoDyn (OTCMKTS:CYDY) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Insider & Institutional Ownership

1.6% of BioLineRx shares are held by institutional investors. Comparatively, 5.1% of CytoDyn shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Comparatively, 0.5% of CytoDyn shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares BioLineRx and CytoDyn’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLineRx	-45.34%	-49.74%	-17.54%
CytoDyn	N/A	N/A	-4.40%

Analyst Recommendations

This is a breakdown of current recommendations for BioLineRx and CytoDyn, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	0	0	1	1	3.50
CytoDyn	0	0	0	0	0.00

BioLineRx currently has a consensus target price of $26.00, indicating a potential upside of 548.38%. Given BioLineRx’s stronger consensus rating and higher possible upside, analysts plainly believe BioLineRx is more favorable than CytoDyn.

Earnings & Valuation

This table compares BioLineRx and CytoDyn”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$28.94 million	0.59	-$9.22 million	($8.80)	-0.46
CytoDyn	N/A	N/A	$3.74 million	$0.01	29.35

CytoDyn has lower revenue, but higher earnings than BioLineRx. BioLineRx is trading at a lower price-to-earnings ratio than CytoDyn, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

BioLineRx has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, CytoDyn has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.

Summary

CytoDyn beats BioLineRx on 8 of the 14 factors compared between the two stocks.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

About CytoDyn

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.